Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Clemens Scherzer, M.D.

Co-Author

This page shows the publications co-authored by Clemens Scherzer and Joseph Locascio.
Connection Strength

3.252
  1. Reader response: Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology. 2020 05 19; 94(20):898-899.
    View in: PubMed
    Score: 0.908
  2. Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71.
    View in: PubMed
    Score: 0.650
  3. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat Genet. 2021 06; 53(6):787-793.
    View in: PubMed
    Score: 0.243
  4. ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696.
    View in: PubMed
    Score: 0.228
  5. Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nat Neurosci. 2019 Jan; 22(1):144-147.
    View in: PubMed
    Score: 0.206
  6. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nat Neurosci. 2018 10; 21(10):1482-1492.
    View in: PubMed
    Score: 0.202
  7. ß2-Adrenoreceptor is a regulator of the a-synuclein gene driving risk of Parkinson's disease. Science. 2017 09 01; 357(6354):891-898.
    View in: PubMed
    Score: 0.188
  8. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker study. Neurology. 2014 May 06; 82(18):1666; discussion 1666.
    View in: PubMed
    Score: 0.149
  9. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7.
    View in: PubMed
    Score: 0.143
  10. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A. 2011 Oct 11; 108(41):17141-6.
    View in: PubMed
    Score: 0.125
  11. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16; 104(3):955-60.
    View in: PubMed
    Score: 0.090
  12. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 2017 08; 16(8):620-629.
    View in: PubMed
    Score: 0.046
  13. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann Neurol. 2016 Nov; 80(5):674-685.
    View in: PubMed
    Score: 0.044
  14. PGC-1a, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010 Oct 06; 2(52):52ra73.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.